FiercePharma, by Angus Liu, Jan 29, 2019 Pfizer has launched China’s first pay-for-performance program in oncology with its blockbuster breast cancer drug Ibrance, China Daily reported. Under the new program, called Bo’ai Xin’an, Pfizer promises reimbursement of up to 33.5% of Ibrance costs if an enrolled patient’s disease progresses within four months. The U.S. pharma set […]
19. April 2018 Interview with Anke Holtorf, Managing Director, Health Outcomes Strategies, GmbH on the subject of patient involvement in pharmaceutical market access. Patients are playing an increasingly powerful part in market access, and this was recently explored within a chapter in the newly-published book Pharmaceutical Market Access in Developed Countries. For full text see http://patientfocusedmedicine.org/integrating-patient-insights-challenges-and-opportunities/
We would like to use the opportunity to share with you the link to a new book which has finally been released (fresh from the electronic press!) and to which Anke-Peggy Holtorf has contributed two chapters (“Market Access in Germany” and, together with Nigel Cook, “The Role of Patients in Market Access“). Kockaya G, […]